Nuedexta's Mechanism of Action
Nuedexta, the brand name for dextromethorphan hydrobromide and quinidine sulfate, works by impacting the brain's signaling pathways. Dextromethorphan, the primary active ingredient, is a cough suppressant that also acts on sigma-1 receptors in the brain. Quinidine, a component of Nuedexta, inhibits the enzyme CYP2D6. This inhibition prevents the rapid breakdown of dextromethorphan, thereby increasing its concentration and duration of action in the body [1].
How Does Nuedexta Affect Pseudobulbar Affect?
The exact mechanism by which Nuedexta treats pseudobulbar affect (PBA) is not fully understood, but it is believed to involve the modulation of supraspinal to the spinal reflex pathways. PBA is characterized by sudden, uncontrollable episodes of crying or laughing that are disproportionate to the situation. Nuedexta's action on sigma-1 receptors and its increased bioavailability due to CYP2D6 inhibition are thought to help regulate these emotional responses [1].
When Does Nuedexta Patent Exclusivity End?
Information regarding Nuedexta's patent exclusivity is tracked by resources like DrugPatentWatch.com [2]. Patents provide a period of market exclusivity for innovative drugs. The expiration of these patents can open the door for generic competition [3].
Can Generic Versions of Nuedexta Become Available?
The availability of generic versions of Nuedexta depends on patent expiration and any regulatory approvals for generic drug applications. Once patents expire, and if generic manufacturers meet the U.S. Food and Drug Administration's (FDA) standards for bioequivalence and quality, generic alternatives could be marketed [3].